We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTransense Regulatory News (TRT)

Share Price Information for Transense (TRT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 95.00
Bid: 93.00
Ask: 97.00
Change: 0.00 (0.00%)
Spread: 4.00 (4.301%)
Open: 95.00
High: 95.00
Low: 95.00
Prev. Close: 95.00
TRT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results & Investor Presentation

22 Feb 2022 07:00

RNS Number : 3472C
Transense Technologies PLC
22 February 2022
 

This announcement contains inside information for the purposes of the UK version of the Market Abuse Regulation 596/2014/EU (which is part of UK law by virtue of the European Union (Withdrawal) Act 2018)

 

 

Transense Technologies plc

("Transense" or the "Company")

 

Interim results & Investor Presentation

 

Transense Technologies plc, the developer of specialist sensor systems, reports its interim results for the six months ended 31 December 2021. The Company has continued to deliver strong revenue growth, resulting in being profitable at the pre-tax level and cash generative.

Highlights:

• Total revenue up by 35% to £1.20m (FY21 H1: £0.89m)

• iTrack royalty closing annualised run rate of £1.56m, up nearly 40% since June 2021 (£1.12m) and up 144% since inception in June 2020 (£0.64m)

• Revenues from Translogik tyre probes up 15% on FY21 H1

• EBITDA* of £0.20m (FY21 H1: £0.06m)

• Profit before taxation of £0.08m (FY21 H1: Loss of £0.05m)

• Earnings per share of 0.69 pence (FY 21 H1: 0.29 pence)

• Net cash at end of period of £1.07m (30 June 2021: £1.04m), increasing to £1.50m at 31 January 2022 following receipt of final quarter iTrack royalty payment

• Board and SAW team strengthened by new appointments

• Share buy back plan proposed

*Earnings before interest, tax, depreciation and amortisation

Commenting on the results and prospects, Executive Chairman of Transense, Nigel Rogers, said:

"These results further demonstrate the robust nature of our business strategy, with commercial income from royalties and probe sales increasing their contribution. These steady sources of revenue have enabled us to make further controlled investment into our SAW business, where the development of our capabilities continues in parallel with increasing prospects for future commercial success.

 

"The Board expects the Company to continue on a high growth trajectory, with minimal additional spend and a consequential low downside risk profile. With the availability of uncommitted cash and a growing distributable reserves balance, the directors plan to initiate a programme of share buybacks to address the short term effects of current market conditions and protect prospects for the delivery of longer-term shareholder value."

 

Investor Presentation: 4pm today, Tuesday 22 February 2022

Nigel Rogers (Executive Chairman) and Melvyn Segal (Chief Financial Officer) will provide a presentation on the Company and its Interim Results at 4pm today, Tuesday 22 February 2022. The presentation will be hosted through the digital platform Investor Meet Company.

To attend the presentation, investors can sign up to Investor Meet Company for free and select to meet Transense Technologies plc via the following link: https://www.investormeetcompany.com/transense-technologies-plc/register-investor. Investors who have already registered and selected to meet the Company will automatically be invited to the presentation.

Questions can be submitted before the event to transense@walbrookpr.com or in real time during the presentation via the "Ask a Question" function. 

This interim results report will not be posted to shareholders but will be available on the Company's website later today along with the investor presentation.

 

 

For further information please visit www.transense.com or contact:

Transense Technologies plc

Nigel Rogers (Executive Chairman)

Melvyn Segal (CFO)

Via Walbrook PR

Allenby Capital (Nominated Adviser and Broker)

Jeremy Porter/George Payne (Corporate Finance)

Tony Quirke (Equity Sales)

Tel: +44 (0)20 3328 5656

Walbrook PR

Tom Cooper/Nick Rome/Nicholas Johnson

Tel: +44 (0)20 7933 8780

Transense@walbrookpr.com

 

 

Notes to Editors:

Transense develops and supplies wireless sensor technology and systems. The Company has three business areas:

· SAW, patent protected Surface Acoustic Wave sensor technology that provides real time measurement of torque, temperature, pressure and strain, that is used to improve efficiency, performance and safety of propulsion systems and machinery;

· Translogik, smart, connected commercial vehicle tyre inspection equipment, used by vehicle fleets to more easily gather and maintain accurate tyre safety and condition data; and

· iTrack, a tyre pressure monitoring system for off-highway machinery, licensed exclusively to Bridgestone Corporation, the world's largest tyre producer, under a ten-year deal.

Target market sectors include automotive, aerospace and industrial machinery. The Group's strategy is to leverage excellence in innovation, know-how in wireless sensor technologies and form industry partnerships in these global growth sectors to maximise shareholder value through sustained revenue growth from all three principal technologies - SAW, iTrack and Translogik.

Transense is headquartered in Oxfordshire, UK, and was admitted to trading on AIM, a market operated by the London Stock Exchange (AIM: TRT), in 1999.

For further information please contact transense@walbrookpr.com

 

 

 

Transense Technologies plc

Chairman's Statement

I am pleased to report interim financial results which further demonstrate the robust nature of our business strategy, with commercial income from royalties and probe sales increasing their contribution. These steady sources of revenue have enabled us to make further controlled investment into our SAW business, where the development of our capabilities continues in parallel with increasing prospects for future commercial success.

 

Business strategy

The business strategy of the Company remains to develop innovative sensing solutions across a range of applications, which are commercialised either through the launch of products and services to customers or by forming strategic alliances with partner organisations. Value is realised through a combination of commercial income, royalties, licensing income and capital gains on disposals.

Business review

iTrack royalty income

In June 2020, the Company granted an exclusive worldwide licence to ATMS Technology Limited ("ATMS"), a wholly-owned subsidiary of Bridgestone Corporation Japan (Bridgestone), covering all current and future iTrack technology for a period of ten years. Under the licence, ATMS offers Bridgestone customers worldwide tyre monitoring systems for all off-the-road vehicles using iTrack technology. Transense receives a quarterly royalty payment based upon the number and classification of vehicles upon which the iTrack technology is deployed over a ten year period, at the conclusion of which ATMS will have the option to acquire the technology for a nominal cash sum.

During the six months ended 31 December 2021 the iTrack installed base continued to gather momentum, generating a 76% increase in royalty income compared with the equivalent period last year to £0.66m (FY21 H1: £0.37m). The annualiased run rate of royalty income in Sterling terms increased by nearly 40% during the period, exiting at the rate of £1.56m per annum (30 June 2021 run rate: £1.12m).

Bridgestone has publicly stated that it continues to pursue a mid-term strategy to develop mobility solutions as an integral and growing element of their offer to customers, with a target of securing up to 20% of revenues from digital products. By February 2022, iTrack was installed at more than 40 sites, double the number twelve months previously. They expect the development of their mining solutions business will be further accelerated by the recent acquisition of Otraco, a tyre services provider with a particularly strong presence in two key geographical markets: Australia and Chile. The combination of Bridgestone and Otraco provides further sales opportunities, including the addition of more than 60 sites where Otraco provides tyre management services in these markets. 

Surface Acoustic Wave

Transense is a leader in the development of Surface Acoustic Wave ("SAW") sensor technology. SAW technology provides exceptionally compact and rugged sensor systems that measure torque, strain, pressure and temperature. SAW sensors operate wirelessly and at high speed without the need for a local power source, bringing benefits in applications where real-time values for torque, temperature or other measurements can be used to optimise efficiency, improve safety and increase performance.

Although our SAW technology has been in existence for many years, the structural and management changes brought about by the iTrack licence in June 2020 provided an ideal opportunity to reboot the development of applications and commercialisation. Since that point, the focus of Board attention, the formation of our commercial advisory panel ("SAWCAP") and the strengthening of the management and engineering teams has transformed future prospects.

These results show a small reduction in reported revenue from ongoing customers from £0.11m to £0.07m, however, this was substantially due to short term timing differences and is not considered to be a significant performance indicator in gauging prospects for future success.

In September 2021, a Joint Collaboration Agreement was signed offering our partner, McLaren Applied Limited, exclusivity in the use of our technology for premium motorsport driveline applications in exchange for meeting minimum revenue targets on an annual basis over the duration of the agreement. Initial revenues in the period were not anticipated to be significant, and these will ramp up during the second half of this financial year and continue into subsequent financial years. Joint marketing efforts are planned to raise the profile of the high-performance control systems that McLaren can deliver using our technology, which may also extend beyond the premium motorsport sector.

Revenues from the provision of technical support for the GE ITEP programme were also reduced from the relatively high level last year, as the programme moves from development towards full production. Engine testing begins early this year with First Engine To Test, initiating a multi-year test campaign on eight factory engines, with flight test engine deliveries to the US Government commencing late in 2022 to support aircraft flight testing on four different platforms.

We have continued to expand our reach in business development through the SAWCAP initiative and our increased market presence through social media and direct approaches. The Board was delighted with the appointment of Ryan Maughan FIMechE MSc in a part-time role as Business Development Director in December 2021. His deep knowledge and extensive network of contacts across the highly specialised Power Electronics, Electric Motors and Drives (PEMD) sector is already opening up many potential opportunities for new business.

As Covid travel restrictions begin to ease, we welcome the opportunity to recommence face-to-face meetings with customers and potential customers during the second half of the current financial year, most of whom we have been unable to visit for the past two years. Looking towards the second half, we anticipate increased premium motorsport activity. We are also working with a major OEM in a high value off highway application, with whom we have recently completed a successful test bed trial and expect to move into a second stage field trial later in the year.

In business development, we are exploring the use of SAW technology with two leading aerospace clients and are in exploratory stages of engagement with tier one automotive, industrial and off-highway suppliers. These discussions are at an early stage and, whilst not offering certainty of future success as yet, there is potential to secure customer and/or grant funding to support their further development. Overall, we are pleased with progress in the commercialisation of SAW technology and optimistic towards prospects.

In anticipation of the increase in commercial SAW activity we have committed controlled investment in design and operations through new key engineering appointments, bringing our team up to eight highly skilled and motivated engineers. We have also committed modest capital expenditure of approximately £100,000 to further develop our in-house assembly, test and calibration capabilities to streamline future throughput and facilitate increased pilot production capacity. These operational improvements have been led by Nick Hopkins, who we were delighted to also welcome to the Board in December 2021 as Chief Operating Officer.

Translogik Probes

Our range of tyre tread depth probes provide extremely accurate and reliable tyre data instantly, and is aimed towards service providers, systems integrators and fleet managers in the truck and bus sector. Our product range is designed to be compatible with the tyre management systems of most of the world's leading tyre producers. The new modular TLGX Series range, launched in June 2020, currently has four levels offering progressively enhanced features at a variety of price points.

Revenue from Translogik probes increased by 15% to £0.47m (FY21 H1: £0.41m), with around two thirds of sales attributable to the new range. This rapid adoption has presented opportunities to upsell, hence gross margin improved slightly from 52.0% to 54.4% despite significant increases in component costs. Accordingly, it is likely that the older Gen 1 product will be subject to a last time buy programme during the second half of the financial year. The current global shortage of electronic components has not impacted probe sales to date, although sourcing components remains a challenge and appropriate action is being taken to mitigate any shortages until the supply chain returns to normal.

In addition to an increased level of enquiries from independent fleet users, development work is underway to align the TLGX range even more closely with the fleet management systems of a select group of leading tyre manufacturers, which is expected to drive further increases in demand in coming months.

 

Financial review

 

Key performance indicators

 

The Board considers the following to be key performance indicators:

 

 

FY 2022

FY 2021

 

Interim

(unaudited)

Interim

(unaudited)

Full Year

(audited)

 

£'000

£'000

£'000

Turnover

1,203

895

1,773

Gross Profit

986

695

1,388

EBITDA

196

56

61

Profit/(Loss) before Taxation

82

(53)

(157)

Profit after Taxation

114

48

156

EPS (pence)

0.69

0.29

0.96

Cash

1,071

1,050

1,046

Net increase/(decrease) in cash

25

(143)

(147)

 

Reported results

Revenues for the six months from continuing operations increased by 35% to £1.20m (FY21 H1: £0.89m).

Royalty income generated by iTrack technology increased by 76% to £0.66m (FY21 H1: £0.37m). The installed base increased by 35% during the past six months, and the annualised royalty run rate at 31 December 2021 was 167% higher than the opening US Dollar run rate in June 2020 and an increase of 144% in Sterling terms.

SAW revenues reduced slightly to £0.07m for the period (FY21 H1: £0.11m). Whilst SAW activities continue to incur a net loss, the Board is satisfied that the current level of operating costs is appropriate to the prospects of future commercial success.

Translogik probe revenues increased by 15% to £0.47m, generating a net profit contribution of £0.19m to the Company's results.

Operating expenses in the period increased to £0.90m (FY21 H1: £0.79m) and the Company delivered EBITDA* from continuing operations of £0.20m (FY21 H1: £0.06m).

The net profit before taxation from continuing operations was £0.08m (FY21 H1: loss of £0.05m) and, after recognition of the R&D tax credit and deferred tax, the net profit after taxation attributable to shareholders was £0.11m (FY21 H1: £0.05m). Earnings per share amounted to 0.69 pence (FY21 H1: 0.29 pence).

*Earnings Before Interest, Depreciation and Amortisation as set out in Note 4.

Cash flow and financial position

Net cash inflow from operating activities before movements in working capital amounted to £0.24m (FY21 H1: outflow of £0.08m).

Net cash balances at the end of the period stood at £1.07m (30 June 2021: £1.05m) and net assets stood at £2.57m (30 June 2021: £2.34m). Net cash as at 31 January 2022 increased to £1.50m following receipt, in January 2022, of the quarterly royalties from Bridgestone for the period to 31 December 2021. The Board has assessed the financial and operational needs of the business over the next twelve months taking into account a range of contingencies, and the directors are satisfied that the Company has access to adequate sources of finance.

Accordingly, the Board considers that the Company will have sufficient resources to continue in operational existence for the foreseeable future, and has adopted the going concern basis of accounting.

Share buy backs

The Company's share price over the period rose from 90.5p on 1 July 2021 to a peak of 122.5p on 5 November 2021, before falling back to close the six months at 31 December 2021 at 80.5p and subsequently has been as low as 67.0p more recently. In the opinion of the directors, this unusual short term volatility has little or no correlation with the underlying performance of the business or any material change in prospects. Rather, the share price appears to move in response to small changes in the marginal supply and demand for shares, with thin trading volumes in an illiquid market. Accordingly, the Board is planning for the Company to commence a programme of share buybacks, in order to mitigate the effects of short term supply excess and promote the preservation of long term shareholder value, and to offset the dilutive impact of share awards to directors and employees.

Outlook and prospects

The Company is now experiencing good growth in the royalty income from iTrack, and is aware of further opportunities to grow sales of the Translogik probe business.

 

Investment in the development of our SAW capabilities is carefully controlled, proportionate to the scale and number of available commercial opportunities, and will have minimal impact on future profitability. The additional SAW based head count at employee and Board level, together with the SAWCAP input, has already substantially improved the opportunities to commercialise SAW. The directors continue to focus on maximising the use of our resources and the delivery of future success.

 

Accordingly, the directors are confident that the Company can continue to deliver results on a growth trajectory, whilst carrying corespondingly low risk. Furthermore, the share buy back programme we intend to propose today will enable the Company to acquire shares during any future periods in which market conditions cause any unjustified weakness in the share price.

 

Nigel RogersExecutive Chairman22 February 2022

 

 

 

 

Transense Technologies plc

 

 

 

 

Condensed Statement of Comprehensive Income

 

 

 

 

 

 

 

 

Half year to

 

Half year to

 

Full year to

 

 

31 Dec 21

 

31 Dec 20

 

30 Jun 21

 

 

(Unaudited)

 

(Unaudited)

 

(Audited)

 

 

£'000

 

£'000

 

£'000

Continuing operations

 

 

 

 

 

Revenue

 

1,203

 

895

 

1,773

Cost of sales

 

(217)

 

(200)

 

(385)

Gross profit

 

986

 

695

 

1,388

Operating costs

(898)

 

(790)

 

(1,581)

 

 

 

 

 

 

Operating profit/(loss)

 

88

 

(95)

 

(193)

Financial expense

 

(6)

 

(6)

 

(12)

Other income

 

-

 

48

 

48

Profit/(Loss) before taxation

82

 

(53)

 

(157)

Taxation

 

32

 

101

 

313

Profitfor the period from continuing operations

114

 

48

 

156

         

 

 

 

 

Transense Technologies plc

 

 

 

 

 

Condensed Statement of Financial Position

 

 

 

 

 

 

 

 

 

 

31 Dec 21

 

31 Dec 20

 

30 Jun 21

 

 

(Unaudited)

 

(Unaudited)

 

(Audited)

 

 

£'000

 

£'000

 

£'000

Non current assets

 

 

 

 

 

Property, plant and equipment

201

 

248

 

211

Intangible assets

 

731

 

815

 

770

Deferred tax

 

68

 

 

 

47

 

 

1,000

 

1,063

 

1,028

Current assets

 

 

 

 

 

 

Inventory

108

 

61

 

73

Corporation tax receivable

71

 

100

 

60

Trade and other receivables

731

 

403

 

564

Cash and cash equivalents

1,071

 

1,050

 

1,046

 

 

1,981

 

1,614

 

1,743

Total assets

 

2,981

 

2,677

 

2,771

Current liabilities

 

 

 

 

 

 

Trade and other payables

(269)

 

(225)

 

(260)

Lease liabilities

(63)

 

(63)

 

(65)

Total liabilities

 

(332)

 

(288)

 

(325)

Non current liabilities

 

 

 

 

 

 

Lease liabilities

 

(75)

 

(136)

 

(104)

 

 

 

 

 

 

 

Total liabilities

 

(407)

 

(424)

 

(429)

 

 

 

 

 

 

 

Net assets

 

2,574

 

2,253

 

2,342

Capital and reserves

 

 

 

 

 

Share capital

 

1,644

 

5,451

 

1,631

Share premium

 

65

 

2,591

 

-

Share based payments

 

122

 

63

 

82

Accumulated profit/(loss)

 

743

 

(5,852)

 

629

Shareholders' funds

2,574

 

2,253

 

2,342

 

 

 

 

 

 

 

 

 

 

 

Transense Technologies plc

Condensed Statement of Changes in Equity (Unaudited)

 

 

Share capital

Share premium account

Share based payments

Retained earnings

Total equity

 

 

 

£'000

£'000

 

£'000

£'000

£'000

 

 

 

 

 

 

 

 

 

Balance at 1 July 2020

5,451

2,591

41

(5,900)

2,183

 

 

 

 

 

 

 

 

 

Comprehensive income for the year:

 

 

Profit for the year

-

-

-

156

156

 

Share based payment

-

-

41

-

41

 

Share capital reduction

(3,820)

(2,591)

-

6,411

-

 

Expenses of capital reduction

-

-

-

(38)

(38)

 

 

 

 

 

 

 

 

Balance at 30 June 2021

1,631

-

82

629

2,342

 

 

 

 

 

 

 

 

 

Comprehensive income for the period:

 

Profit for the period

-

-

-

114

114

 

Share based payment

-

-

40

-

40

 

Warrants exercised

13

65

-

-

78

 

 

 

 

 

 

 

 

Balance at 31 December 2021

1,644

65

122

743

2,574

 

                 

 

 

 

Transense Technologies plc

Condensed Statement of Cash Flows

 

 

Half year to

 

Half year to

 

Full year to

 

 

31 Dec 21

 

31 Dec 20

 

30 Jun 21

 

 

(Unaudited)

 

(Unaudited)

 

(Audited)

 

 

£'000

 

£'000

 

£'000

Cash flow from operating activities

 

 

 

 

 

Profit for the period

114

 

48

 

156

Adjustments for:

 

 

 

 

 

Taxation

(32)

 

(101)

 

(313)

Net financial expense

6

 

6

 

12

Depreciation of property, plant and equipment

43

 

43

 

85

Amortisation and impairment of intangible assets

65

 

60

 

121

Share based payments

40

 

22

 

41

 

 

 

 

 

 

Operating cash flows before movements in working capital

236

 

78

 

102

 

 

 

 

 

 

 

Change in receivables

(167)

 

37

 

(124)

Change in payables

9

 

(628)

 

(594)

Change in inventories

(35)

 

2

 

(10)

Cash used in operations

43

 

(511)

 

(626)

Taxation recovered

-

 

176

 

381

Net cash used in operations

43

 

(335)

 

(245)

 

 

 

 

 

 

 

Cash flows from investing activities

 

 

 

 

 

Acquisition of property, plant & equipment

(33)

 

(1)

 

(6)

Acquisition of intangible assets

(25)

 

(31)

 

(47)

Proceeds from disposal of trade and assets (net of cash)

-

 

1,236

 

1,237

Net cash used in investing activities

(58)

 

1,204

 

1,184

 

 

 

 

 

 

 

Cash flows from financing activities

 

 

 

 

 

Capital reduction costs

-

 

-

 

(38)

Warrants exercised

78

 

-

 

-

Loans repaid

-

 

(976)

 

(976)

Interest paid

(6)

 

(6)

 

(12)

Payment of lease liabilities

(31)

 

(30)

 

(60)

Net cash generated/(used) for financing activities

41

 

(1,012)

 

(1,086)

 

 

 

 

 

 

 

Net increase/(decrease) in cash and cash equivalents

25

 

(143)

 

(147)

Unrealised currency translation gain

-

 

-

 

-

Cash and cash equivalents at beginning of period

1,046

 

1,193

 

1,193

Cash and cash equivalents at end of period

1,071

 

1,050

 

1,046

 

 

 

 

 

 

 

 

 

 

Notes to the Interim results for the six months to 31 December 2021

 

1. Reporting Entity and Basis of Preparation

Transense Technologies plc ("the Company") is a company incorporated in the United Kingdom under the Companies Act 2006. These condensed interim financial statements are presented in pounds sterling, rounded to the nearest thousand.

 

The financial statements of the Group are available upon request from the Company's registered office or at www.transense.com

 

2. Going Concern

The Board has considered the financial position and future plans of the Company and is satisfied that the Company will have adequate resources to continue in operational existence for the foreseeable future. Accordingly, these interim financial statements have been prepared on a going concern basis.

 

3. Accounting policies

The Condensed Financial Statements for the half yearly report for the six months ended 31 December 2021 have been prepared using accounting policies and methods of computation consistent with those set in Transense Technologies plc's Annual Report and Financial Statements for the year ended 30 June 2021. There has been no change to any accounting policy since the date of that report.

 

4. Segmental analysis

Continuing Revenue by region

Half year to

Half year to

Full year to

 

31 Dec 21

31 Dec 20

30 Jun 21

 

(Unaudited)

(Unaudited)

(Audited)

 

£'000

£'000

£'000

North America

211

111

244

South America

64

38

82

Australia

18

17

28

UK & Europe

226

261

318

Rest of the World

24

94

269

Royalty income

660

374

832

Total

1,203

895

1,773

 

Half Year to 31 Dec 2021

IT Royalties

£'000

SAW

£'000

Probes

£'000

Admin

£'000

Total

£'000

Turnover

660

73

470

-

1,203

Gross profit

660

70

256

-

986

Operating costs

-

(442)

(62)

(286)

(790)

EBITDA*

660

(372)

194

(286)

196

Depreciation and amortisation

(22)

(86)

-

-

(108)

Finance expenses

-

(6)

-

-

(6)

Profit/(loss) before taxation

638

(464)

194

(286)

82

Taxation

5

6

-

21

32

Profit/(loss) after taxation

643

(458)

194

(265)

114

 

Half Year to 31 Dec 2020

IT Royalties

£'000

SAW

£'000

Probes

£'000

Admin

£'000

Total

£'000

Turnover

374

114

408

-

896

Gross profit

374

109

212

-

695

Operating costs

-

(383)

(60)

(244)

(687)

Other income

-

48

-

-

48

EBITDA*

374

(226)

152

(244)

56

Depreciation and amortisation

(22)

(78)

(2)

-

(102)

Finance expenses

-

(7)

-

-

(7)

Profit/(loss) before taxation

352

(311)

150

(244)

(53)

Taxation

50

51

-

-

101

Profit/(loss) after taxation

402

(260)

150

(244)

48

 

 

Year to 30 June 2021

IT Royalties

£'000

SAW

£'000

Probes

£'000

Admin

£'000

Total

£'000

Turnover

832

177

764

-

1,773

Gross profit

832

171

385

-

1,388

Operating costs

-

(749)

(111)

(515)

(1,375)

Other income

-

48

-

-

48

EBITDA*

832

(530)

274

(515)

61

Depreciation and amortisation

(47)

(156)

(3)

-

(206)

Finance expenses

-

(12)

-

-

(12)

Profit/(loss) before taxation

785

(698)

271

(515)

(157)

Taxation

102

164

-

47

313

Profit/(loss) after taxation

887

(534)

271

(456)

156

 

*Earnings before interest, tax, depreciation and amortisation

 

5. Corporation tax and deferred tax

The Company is entitled to a Corporation Tax credit in respect of expenditure on Research and Development. In January 2022, the Company received £0.07m R & D tax credit from HMRC in respect of the Financial Year 2021. The benefit of this credit was substantially recognised in the FY 21 (£0.06m) and the balance has been recognised in the accounts to 31 December 2021.

The Company has approximately £23m of Corporation Tax losses which, subject to agreement by HM Revenue and Customs, are available for offset against future profits of the same trade. There is no expiry date for tax losses, however there is an annual restriction of £5m plus half of the surplus above £5m. As the Company moved into profitability Deferred Tax was recognised for the first time in the full years accounts to 30 June 2021 by recognising a credit relating to FY 22 estimated results.

 

The deferred tax charge and credit in H1 reflects the charge reversing the credit for the pre tax profit in H1 and an additional credit reflecting the forecast pre tax profits for the full year FY22 and FY23 now a profitable underlying trend is in place. It is recognised on the basis of an effective rate for the full year FY22 with an estimated credit of approximately £0.25m to be recognised in the full year accounts.

 

6. Earnings per share

 

 

31 December 2021

31 December 2020

30 June 2021

 

Shares

Shares

Shares

Weighted average number of shares in the period

16,402,998

16,307,282

16,307,282

 

 

 

 

Earnings per share

 

 

 

From continuing operations

0.69p

0.29p

0.96p

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR KZGZZLMVGZZM
Date   Source Headline
17th Apr 20246:00 pmRNSTransaction in Own Shares & TVR
15th Apr 20242:51 pmRNSTransaction in Own Shares & TVR
28th Mar 20245:00 pmRNSTotal Voting Rights
25th Mar 20243:35 pmRNSTransaction in Own Shares & TVR
20th Mar 20249:10 amRNSRyan Maughan appointed as Managing Director
29th Feb 20245:00 pmRNSTotal Voting Rights
21st Feb 20242:40 pmRNSHolding(s) in Company
19th Feb 20247:00 amRNSInterim Results & Investor Presentation
15th Feb 20247:00 amRNSHolding(s) in Company
2nd Feb 20245:41 pmRNSTransaction in Own Shares & TVR
31st Jan 20245:00 pmRNSTotal Voting Rights
12th Jan 20247:00 amRNSDirector/PDMR Shareholding
11th Jan 20249:52 amRNSTransaction in Own Shares & TVR
8th Jan 20247:00 amRNSTranslogik Update – Appointment of Sales Director
1st Dec 20237:00 amRNSGrant of share options to Director and employee
30th Nov 20235:00 pmRNSTotal Voting Rights
30th Nov 202311:11 amRNSDirector/PDMR Shareholding
29th Nov 20233:01 pmRNSDirector/PDMR Shareholding
29th Nov 202310:45 amRNSResult of AGM
29th Nov 20237:00 amRNSAGM Statement & Trading Update
24th Nov 20231:11 pmRNSHolding(s) in Company
9th Nov 202312:12 pmRNSDirector/PDMR Shareholding
6th Nov 20234:48 pmRNSTransaction in Own Shares & TVR
25th Oct 202310:00 amRNSPosting of Annual Report & Notice of AGM
16th Oct 20233:23 pmRNSHolding(s) in Company
3rd Oct 20236:00 pmRNSHolding(s) in Company
28th Sep 20235:22 pmRNSHolding(s) in Company
27th Sep 20233:18 pmRNSHolding(s) in Company
26th Sep 20233:37 pmRNSDirector/PDMR Shareholding
25th Sep 202311:00 amRNSDirector/PDMR Shareholding
25th Sep 20237:00 amRNSFinal Results & Investor Presentation
22nd Sep 20239:25 amRNSHolding(s) in Company
31st Aug 20235:00 pmRNSTotal Voting Rights
29th Aug 20238:30 amRNSTransaction in Own Shares & TVR
23rd Aug 20237:00 amRNSNotice of Results & Investor Presentation
16th Aug 202310:03 amRNSHolding(s) in Company
11th Jul 20237:00 amRNSYear End Trading Update
30th Jun 20235:00 pmRNSTotal Voting Rights
22nd Jun 20234:24 pmRNSTransaction in own shares & TVR
19th Jun 20234:29 pmRNSHolding(s) in Company
16th Jun 20235:57 pmRNSTransaction in own shares & TVR
5th Jun 20237:00 amRNSSAW: Extension of scope of licence agreement
2nd Jun 20232:36 pmRNSTransaction in own shares & TVR
31st May 20235:00 pmRNSTotal Voting Rights
3rd May 20237:00 amRNSNew Automotive eDrive Business Contract
2nd May 202312:48 pmRNSAppointment of Non-Executive Director
2nd May 202310:23 amRNSTransaction in own shares & TVR
31st Mar 20235:00 pmRNSTotal Voting Rights
27th Mar 20237:00 amRNSGrant of share options to Director and employees
20th Mar 20238:49 amRNSTransaction in Own Shares & TVR

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.